News & Updates
Filter by Specialty:
New algorithm predicts HCC risk in compensated advanced chronic liver disease
A novel algorithm using post-treatment age, albumin, and liver stiffness measurement (LSM), among other parameters, can accurately stratify patients with compensated advanced chronic liver disease (cACLD) according to their de novo hepatocellular carcinoma (HCC) risk, a new study shows.
New algorithm predicts HCC risk in compensated advanced chronic liver disease
19 Dec 2021Reduced kidney function, urine output tied to kidney nonrecovery in COVID-19 patients
Among critically ill patients with COVID-19, those who present with lower baseline estimated glomerular filtration rate (eGFR) and reduced urine output at the time of kidney replacement therapy (KRT) initiation are more likely to experience kidney nonrecovery, according to a study.
Reduced kidney function, urine output tied to kidney nonrecovery in COVID-19 patients
19 Dec 2021Dietary therapy: Eating the right foods can help modulate IBD
The gut bacteria are crucial to health and the variable that links inflammatory bowel disease (IBD) to diet. What people eat shapes the composition of bugs that live in the gut, and an imbalance in this composition can promote a range of medical conditions, including IBD. It follows that diet may be involved in the development of IBD, and that diet may be a potential therapy, according to an expert.
Dietary therapy: Eating the right foods can help modulate IBD
18 Dec 2021Ambulatory better than central BP at predicting death, cardiovascular events in dialysis patients
Central blood pressure (BP) is associated with all-cause mortality and cardiovascular events in haemodialysis patients, reveals a study. However, its prognostic value is not superior to ambulatory peripheral BP.
Ambulatory better than central BP at predicting death, cardiovascular events in dialysis patients
18 Dec 2021IBD therapies do not increase risk of contracting COVID-19 after immunization
Using biologic/small molecules*, systemic steroids, or other agents** to treat patients with inflammatory bowel disease (IBD) does not increase the rate of SARS-CoV-2 infection at 3 and 6 months post-immunization, according to a study presented at AIBD 2021.
IBD therapies do not increase risk of contracting COVID-19 after immunization
18 Dec 2021Early vedolizumab treatment uncommon in IBD
In patients with inflammatory bowel disease (IBD), the likelihood of early treatment with vedolizumab is low, a finding that diverts from guideline recommendations, according to a real-world study presented at AIBD 2021.